

# ASX Announcement



Medibio Limited – 3 March 2022

## **Non-Renounceable Entitlement Offer Shareholder Withdrawal Rights**

**Melbourne, Australia and Minneapolis, MN – 3 March 2022: Medibio Limited (“MEB” or “Medibio”)** (ASX: MEB) (OTCPINK: MDBIF) refers to its announcement dated 1 March 2022 with regard to the mutual termination of the Underwriting Agreement with CPS Capital Group Pty Ltd for its Non-Renounceable Entitlement Offer (“**Entitlement Offer**”). The Company advises that it is offering withdrawal rights to those shareholders who have already participated in the Entitlement Offer.

In order to withdraw any subscription funds, those shareholders that have subscribed can call the offer information line through the Company’s Share Registry, Computershare on 1300 855 080 (within Australia) or +61 3 9415 4000 (outside Australia) Monday to Friday 8:30am – 5:00pm (AEDT).

The Company will allow withdrawals up until 5:00pm (AEDT), Tuesday, 8 March 2022 .

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

### **For Further information:**

Mathew Watkins  
Company Secretary  
T: +61 3 9692 7222

### **About Medibio Limited**

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).